(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Giant ‘toothed’ birds flew over Antarctica 40 million to 50 million years ago - 2Everyone knows F1 is for the girls. I wandered into the Las Vegas desert to find out why.
- 3Embrace the Outside: Exercises and Entertainment
- 4Must-See Attractions in France
- 5A definitive Handbook for Securities exchange Money management
- Instructions to Upgrade the Mechanical Highlights of Your Shrewd Bed for a Superior Night's Rest
- Which camera do you believe is great for first-time clients? !
- German finance minister sees advantages of smartphones in schools
- Couch Styles of 2024: What's Moving
- US FDA approves Kura-Kyowa's blood cancer therapy
- What really happens when 140 reality stars come face to face with their biggest fans
- Investigating Free Cell Phones: What You Really want to Be aware
- Instructions to Perform Fundamental Upkeep on Your Slam 1500.
- The Most Moving TED Talks You Want to Watch
